Characteristics of patients receiving extended treatment after incident venous thromboembolism

• DOI: 10.1111/bcpt.13637
• Publication Date: 2021-07-10T00:39:33Z
• Authors: Ida Ehlers Albertsen; Martin Jensen; Khaled Abdelgawwad; Mette Søgaard; Torben Bjerregaar...; Peter Brønnum Nie...
• Keywords: Apixaban; Clinical Practice

Abstract Given high recurrence risk after venous thromboembolism (VTE), guidelines recommend extended dose rivaroxaban (10 mg OD) or apixaban (2.5 BID) to be considered 6 months of initial treatment. This study aimed provide insight into clinical practice regarding the use preventive treatment and describe duration Linkage nationwide health registers identified all in‐ outpatients with VTE from April 2017 through 2018. Hazard ratios (HR) 95% confidence intervals (CIs) were calculated adjusting for other VTE‐related factors. The included 6030 patients VTE. Among users, 2.2% ( n = 113) received 10‐mg mean 9.4 (SD 3.1) standard For apixaban, 4.7% 40) 2.5‐mg 8.0 3.9). After adjustments, incident pulmonary embolism (HR 1.81 CI 1.12;2.91) trauma/fracture 1.42 0.46;4.43) associated switching dose, whereas unprovoked less likely receive 0.68 0.30;1.55). Less than 3% Even though international suggest that risk–benefit balance is in favour treatment, this was yet translated as Studies using contemporary data are warranted investigate routine recurrence.